Eli Lilly and Company
893 S Delaware St
Indianapolis
Indiana
46285
United States
Tel: 317-276-2000
Website: http://www.lilly.com/
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to make life better for people around the world. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of disease, and giving back to communities through philanthropy and volunteerism. We also have been committed to investing in our employees – through competitive salaries, training and development, health, and the opportunity to do good. The pharmaceutical industry is a complex, rapidly changing environment and we’re looking for people who are determined to make life better for people around the world. Visit https://careers.lilly.com for more information.
Stock Symbol: LLY
Stock Exchange: NYSE
We discover life-changing medicines. We commit to diversity and inclusion. We volunteer millions of hours. We make life better. We are Lilly.
2057 articles with Eli Lilly and Company
-
Mylan Launches First Generic for Adcirca® Tablets
8/13/2018
Global pharmaceutical company Mylan today announced the U.S. launch of Tadalafil Tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and Company's Adcirca®.
-
Magnolia Neurosciences Corporation, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.
-
Last week, Teva Pharmaceutical released what tried to be an optimistic second-quarter financial report, despite revenues that had decreased by 18 percent and softening sales of its biggest product, Copaxone.
-
August 3 Research Roundup: Cannabidiol and Pancreatic Cancer, Metformin, Thalidomide and More
8/3/2018
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Elanco Animal Health Files IPO Registration Statement
8/2/2018
Eli Lilly and Company announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of common stock.
-
Boston-based biotech company Karuna Pharmaceuticals completed a $42 million Series A financing. The round included the issuance of $22 million in shares upon conversion of debt into equity.
-
Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability
8/1/2018
The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in the U.S.
-
Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute
7/30/2018
Extension of research collaboration focused on enhancing and speeding the process of bringing new and advanced treatments to cancer patients
-
Research published in the journal Nature by researchers at the National Health Research Institutes in Taiwan and the National Institute on Aging, National Institutes of Health in the U.S. suggest that a class of diabetes medications known as GLP-1 analogues may be effective treatments for Parkins...
-
South San Francisco-based Alector closed on a Series E financing worth $133 million. The money will be used to advance the company’s clinical programs and expand its discovery platform.
-
Lilly to Separate Elanco Animal Health with Initial Public Offering
7/24/2018
Company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission
-
Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance
7/24/2018
Second-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined.
-
Transcriptic Selected to Oversee Robotic Cloud Lab Platform for Lilly’s San Diego Biotechnology Center
7/24/2018
Transcriptic announced today that it has entered into a multi-year collaboration agreement with Eli Lilly and Company whereby Lilly will license the Transcriptic Common Lab Environment (TCLE) to enable on-demand drug discovery operations at its San Diego Biotechnology Center.
-
Pharma a Significant Driver for Eli Lilly’s 2Q, Company Plans IPO for Animal Health Business
7/24/2018
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year. -
Anima Biotech Announces an Exclusive Collaboration With Lilly for the Discovery and Development of Translation Inhibitors of Several Protein Targets
7/23/2018
Anima Biotech today announced an agreement with Lilly for the discovery and development of translation inhibitors.
-
Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.
-
Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018)
7/20/2018
Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly's focus on making a meaningful difference in the lives of people living with Alzheimer's through clinical development and collaboration.
-
Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease
7/19/2018
The U.S. label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD).
-
Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
7/19/2018
Eli Lilly and Company and Incyte Corporation announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet.
-
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
7/19/2018
Study supports long-term cardiovascular safety of Tradjenta® (linagliptin) in adults with type 2 diabetes